Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer

This is a phase 2 study (the second phase in testing a new drug or combination to see how effect the drug or combination is) of investigational drugs GSK2256098 and Trametinib.
The purpose of the study is to evaluate the antitumor activity of GSK2256098 and Trametinib in patients with advanced pancreatic cancer.

开始日期2016-04-01

申办/合作机构

University Health Network

[+1]

NCT02551653

/ Completed临床1期

A Microdose Study to Evaluate the Biodistribution of [11C]-GSK2256098 in the Lungs and Heart of Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients Using Positron Emission Tomography (PET)

Pulmonary arterial hypertension (PAH) involves the narrowing of blood vessels connected to and within the lungs. Focal adhesion kinase (FAK) is a focal adhesion-associated protein kinase involved in cellular adhesion and spreading processes which leads to stiffening and thickening of blood vessels in lungs. This further increases the blood pressure within the lungs and impairs their blood flow. This study aims to demonstrate biodistribution of FAK inhibitor, GSK2256098, in cardiopulmonary sites i.e. heart and lung tissues. The uptake of 11C-radiolabelled GSK2256098 within the lung and / or heart of healthy subjects and idiopathic pulmonary arterial hypertension (iPAH) patients will be assessed using Positron Emission Tomography (PET). Based on study results the decision as to whether a follow-on phase 2 trial should be initiated to investigate the therapeutic utility of GSK2256098 in iPAH will be decided. Sufficient number of subjects will be screened (up to 30 days prior to scan) to enrol 12 healthy subjects and 12 PAH patients in the study. Enrolled subjects will receive a microdose of [11C]-GSK2256098 on a scanning day which will be followed by the follow-up visit (2-4 weeks post-last dose).

开始日期2015-11-17

申办/合作机构

GSK Plc

NCT02523014

/ Recruiting临床2期IIT

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

开始日期2015-09-28

申办/合作机构

Alliance Foundation Trials LLC

[+4]

100 项与 GSK-2256098 相关的临床结果

登录后查看更多信息

100 项与 GSK-2256098 相关的转化医学

登录后查看更多信息

100 项与 GSK-2256098 相关的专利（医药）

登录后查看更多信息

项与 GSK-2256098 相关的文献（医药）

2024-12-01·Biochemical and Biophysical Research Communications

Modeling of FAK-PROTAC candidates from GSK2256098 analogs for targeted protein degradation

Article

作者: Kumar, Vikas ; Lee, Keun Woo ; Ro, Hyeon-Su ; Parate, Shraddha ; Jung, Tae Sung

Protein inhibition via the traditional drug-designing approach has been shown to be an effective method for developing numerous small-molecule-based therapeutics. In the last decade, small inhibitors-guided protein degradation has arisen as an alternative method with the potential to fulfill the drug requirement for undruggable targets. Focal adhesion kinase (FAK) is a crucial modulator of the growth and spread of tumors, apart from it also acts as a scaffold for signaling of other proteins. FAK inhibitors have thus far had unsatisfactory results in clinical trials for cancer applications. Unlike prior attempts to control FAK expression, which were restricted to kinase domain inhibition with limited success in clinical research, protein degradation has the potential to concurrently disrupt FAK's kinase and scaffolding function. Recently, several FAK degraders were reported based on FAK Type I inhibitors using complex chemical synthesis approaches. Interestingly, recently a ternary complex was published revealing the binding mode of the FAK-PROTAC-E3 complex. This complex opens an avenue for the development of rational PROTAC design against FAK protein. Therefore, in the present study, we selected the most active Type I FAK inhibitor GSK2256098. The binding mode of the inhibitor prompted us to identify the most suitable analog for PROTAC design. We have identified a high-affinity analog that is suitable for PTOTAC design through the application of molecular docking (MD) and molecular dynamics simulations (MDS). Further based on the ternary FAK-PROTAC-E3 complex we build a binary complex FAK-Hit-E3-VHL between both proteins. Using the structure-based approach ten different potential FAK PROTACs candidates were designed. The stability of the complexes was analyzed using MDS and binding free energies were used to predict the binding affinity. Finally, based on desirable intermolecular interactions with the target and E3 ligase ProTAC4 was selected as the best candidate when compared with known FAK PROTAC GSK215.

2024-11-01·Journal of Cellular Physiology

Ankrd1 inhibits the FAK/Rho‐GTPase/F‐actin pathway by downregulating ITGA6 transcriptional to regulate myoblast functions

Article

作者: Huang, Cheng ; Hu, Jinling ; Lian, Weisi ; Lei, Minggang ; Kang, Tingting ; Zhong, Qiqi

AbstractSkeletal muscle constitutes the largest percentage of tissue in the animal body and plays a pivotal role in the development of normal life activities in the organism. However, the regulation mechanism of skeletal muscle growth and development remains largely unclear. This study investigated the effects of Ankrd1 on the proliferation and differentiation of C2C12 myoblasts. Here, we identified Ankrd1 as a potential regulator of muscle cell development, and found that Ankrd1 knockdown resulted in the proliferation ability decrease but the differentiation level increase of C2C12 cells. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyzes as well as RNA‐seq results showed that Ankrd1 knockdown activated focal adhesion kinase (FAK)/F‐actin signal pathway with most genes significantly enriched in this pathway upregulated. The integrin subunit Itga6 promoter activity is increased when Ankrd1 knockdown, as demonstrated by a dual‐luciferase reporter assay. This study revealed the molecular mechanism by which Ankrd1 knockdown enhanced FAK phosphorylation activity through the alteration of integrin subunit levels, thus activating FAK/Rho‐GTPase/F‐actin signal pathway, eventually promoting myoblast differentiation. Our data suggested that Ankrd1 might serve as a potential regulator of muscle cell development. Our findings provide new insights into skeletal muscle growth and development and valuable references for further study of human muscle‐related diseases.

2024-01-01·Gut

FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer

Article

作者: Biankin, Andrew V ; Davidson, Catherine ; von Kriegsheim, Alex ; Kallor, Ashwin Adrian ; Byron, Adam ; Sławińska, Aleksandra Dominika ; Upstill-Goddard, Rosie ; Canel, Marta ; Serrels, Alan ; Alfaro, Javier ; Lonergan, David W

ObjectiveImmunotherapy for the treatment of pancreatic ductal adenocarcinoma (PDAC) has shown limited efficacy. Poor CD8 T-cell infiltration, low neoantigen load and a highly immunosuppressive tumour microenvironment contribute to this lack of response. Here, we aimed to further investigate the immunoregulatory function of focal adhesion kinase (FAK) in PDAC, with specific emphasis on regulation of the type-II interferon response that is critical in promoting T-cell tumour recognition and effective immunosurveillance.DesignWe combined CRISPR, proteogenomics and transcriptomics with mechanistic experiments using a KrasG12Dp53R172Hmouse model of pancreatic cancer and validated findings using proteomic analysis of human patient-derived PDAC cell lines and analysis of publicly available human PDAC transcriptomics datasets.ResultsLoss of PDAC cell-intrinsic FAK signalling promotes expression of the immunoproteasome and Major Histocompatibility Complex class-I (MHC-I), resulting in increased antigen diversity and antigen presentation by FAK-/- PDAC cells. Regulation of the immunoproteasome by FAK is a critical determinant of this response, optimising the physicochemical properties of the peptide repertoire for high affinity binding to MHC-I. Expression of these pathways can be further amplified in a STAT1-dependent manner via co-depletion of FAK and STAT3, resulting in extensive infiltration of tumour-reactive CD8 T-cells and further restraint of tumour growth. FAK-dependent regulation of antigen processing and presentation is conserved between mouse and human PDAC, but is lost in cells/tumours with an extreme squamous phenotype.ConclusionTherapies aimed at FAK degradation may unlock additional therapeutic benefit for the treatment of PDAC through increasing antigen diversity and promoting antigen presentation.

项与 GSK-2256098 相关的新闻（医药）

2023-05-08

·PRNewswire

Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs

DUBLIN, May 8, 2023 /PRNewswire/ -- The "Pancreatic Cancer - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Pancreatic Cancer- Competitive landscape, 2023" report provides comprehensive insights about 250+ companies and 300+ drugs in Pancreatic Cancer Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In March 2023, Adaptimmune Therapeutics plc. and TCR Therapeutics Inc. (NASDAQ: TCRR), announced entry into a definitive agreement under which Adaptimmune will combine with TCR in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms. As a result, and following the closing of the transaction, it is anticipated that the combined company's cash runway will extend into 2026. In February 2023, Akamis Bio, announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include a clinical collaboration with the Cancer Research Institute (CRI) that will focus on advancing novel treatments for pancreatic cancer. As part of the Akamis Bio, PICI, and CRI partnership, NG-350A, an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody, will be evaluated in combination with standard-of-care chemotherapy and the CTLA-4 inhibitor ipilimumab (YERVOY). In February 2023, Gritstone bio, Inc. announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health, to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone's KRAS-directed vaccine candidate, SLATE-KRAS, in a Phase 1 study. Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut). In February 2023, Keymed Biosciences Inc., jointly announced a global exclusive license agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). Under the license agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialization of CMG901 globally. CMG901 is currently in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumors. In January 2023, AIM ImmunoTech Inc. announced it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca. Under the agreement, Erasmus MC is planning to perform an investigator-initiated clinical study, entitled "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect. DURIPANC Study," in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech. Pancreatic Cancer Analytical Perspective In-depth Commercial Assessment: Pancreatic Cancer Collaboration Analysis by Companies The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form. Key Questions Answered Current Treatment Scenario and Emerging Therapies: How many companies are developing Pancreatic Cancer drugs? How many Pancreatic Cancer drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Pancreatic Cancer and their status? What are the key designations that have been granted to the emerging and approved drugs? Key Players Panbela Therapeutics ERYtech Pharma Jiangsu HengRui Medicine Co., Ltd. FibroGen Novartis AG AB Science TME Pharma AG Intensity Therapeutics Silenseed LTD SynerGene Therapeutics Elevation oncology Salspera LLC Redx Pharma Plc AIM ImmunoTech Inc. Rain Oncology Jazz Pharmaceuticals Invyte Corporation Immodulon Therapeutics Ltd GSK plc Merck Sharp & Dohme LLC Roche Helsinn Healthcare SA Argenus Inc. Actuate Therapeutics OSE Immunotherapeutics Incyte Corporation Galera Therapeutics CSPC ZhongQi Pharmaceutical Technology Astellas Pharma Global Development, Inc. NanOlogy Theriva Biologics AstraZeneca Berg, LLC Agenus ABVC BioPharma, Inc. Boehringer Ingelheim Alligator Bioscience CARsgenTherapeutics Co.,Ltd Purple Biotech Ltd. Lisata Therapeutics Chongqing Precision Biotech Co., Ltd Cybrexa Therapeutics Bold Therapeutics BioNTech SE Bristol-Myers Squibb DEKA Biosciences Senhwa Biosciences Cue Biopharma Carisma Therapeutics Inc Key Products Olaptesed pegol INT230-6 SBP-101 Masitinib NIS793 siG12D LODER SGT-53 Seribantumab Salmonella-IL2 RXC004 Rintatolimod RAIN-32 Lurbinectedin Retifanlimab IMM-101 GSK2256098 Belzutifan Atezolizumab Anamorelin AGEN1423 Elraglusib OSE2101 Epacadostat GC4711 Docetaxel Zolbetuximab NanoPac VCN-01 Danvatirsen BPM31510 Botensilimab ABV-1703 BI 907828 Mitazalimab CT041 CM24 CEND-1 CEA-targeted CAR-T cells CBX-12 BOLD-100 BNT141 BMS-813160 DK210 CX-5461 CUE-102 CT-0508 For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

免疫疗法引进/卖出疫苗临床1期抗体药物偶联物

100 项与 GSK-2256098 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16106

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺癌	临床2期	加拿大	GSK Plc	2016-04-01
胰腺癌	临床2期	加拿大	GSK Plc	2016-04-01
脑膜瘤	临床2期	美国	GSK Plc	2015-09-28
2型神经纤维瘤病	临床2期	美国	GSK Plc	2015-09-28
晚期恶性实体瘤	药物发现	英国	GSK Plc	2013-11-18
复发性胶质母细胞瘤	药物发现	澳大利亚	GSK Plc	2010-07-27
复发性胶质母细胞瘤	药物发现	英国	GSK Plc	2010-07-27
复发性胶质母细胞瘤	药物发现	法国	GSK Plc	2010-07-27
间皮瘤	药物发现	英国	GSK Plc	-
间皮瘤	药物发现	法国	GSK Plc	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02523014 (Alliance A071401, ASCO2020) 人工标引	临床2期	脑膜瘤 NF2 Mutation	36	GSK-2256098 (Grade I meningiomas)	(觸鹽襯製簾簾簾顧獵齋) = 鹹遞構鏇製糧蓋構製廠構餘積顧淵繭憲憲積淵 (艱衊壓壓製蓋艱餘選遞, 52 ~ 98)	积极	2020-05-25
				GSK-2256098 (Grade II/III meningiomas)	(觸鹽襯製簾簾簾顧獵齋) = 選餘選鹽構餘鏇艱鬱遞構餘積顧淵繭憲憲積淵 (艱衊壓壓製蓋艱餘選遞, 16 ~ 55)
NCT02551653 (CTgov)	临床1期	特发性肺动脉高压	10	GSK2256098 (PAH Participants)	製鑰膚願簾獵繭艱鑰簾(鹽壓顧淵顧衊廠蓋顧構) = 醖築淵製顧獵醖願衊願顧築餘網鹹壓獵窪鬱蓋 (艱膚簾糧夢積鏇憲淵憲, 壓觸壓製壓醖鏇鑰觸構 ~ 顧憲顧憲憲鹽鬱製網鏇) 更多	-	2018-08-17
				GSK2256098 (Healthy Volunteers)	製鑰膚願簾獵繭艱鑰簾(鹽壓顧淵顧衊廠蓋顧構) = 襯積糧艱憲齋夢簾製齋顧築餘網鹹壓獵窪鬱蓋 (艱膚簾糧夢積鏇憲淵憲, 鏇糧膚淵艱築築齋艱網 ~ 醖製醖遞觸廠範廠鏇遞) 更多
NCT02428270 (ASCO_GI 12018 \| ASCO_GI 22018) 人工标引	临床2期	晚期胰腺导管腺癌二线	16	trametinib+GSK2256098	(積選鑰蓋鑰艱願築衊廠) = 糧簾繭衊積構鏇夢構餘夢憲獵糧夢廠顧獵餘網 (鹽鹹顧顧觸蓋醖艱繭糧, 1.5 ~ 1.8) 更多	不佳	2018-01-19
NCT01938443 (ASCO2015) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	24	GSK2256098+trametinib (total population)	(醖獵製膚廠繭範鏇壓艱) = 鏇淵觸繭繭範餘襯構獵淵膚觸顧築蓋願醖顧構 (廠構選觸積願網積餘積 )	积极	2015-05-20
				GSK2256098+trametinib (mesothelioma pts)	(觸構鹹醖遞範鑰鏇鑰廠) = 鏇繭選醖衊鹽獵壓顧醖醖簾壓鹽範艱製齋觸築 (願淵遞鹽鏇築鏇憲蓋網 )
NCT01138033 (ASCO2012)	临床1期	HR阳性/HER2低表达实体瘤	57	GSK2256098	(獵選醖醖壓築艱蓋齋齋) = 艱鹽壓廠醖鹹觸積簾鏇鏇鑰網繭淵衊餘鹽憲餘 (夢衊衊構廠憲願憲淵齋 ) 更多	-	2012-05-20